Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
US dollar bond movements | Sun Hung Kai Properties SUNHUN 1.89 01/17/28 price rose 1.736% to 96.010.
16/05/2025
On May 16, SUNHUN 1.89 01/17/28 issued by New World Development is currently priced at 96.010, up +1.736% with a yield of 3.515%.
Latest
3 m ago
Dahua Group and other investors have established a technology company with business related to the Internet of Things.
3 m ago
Elderly person with serious illness dies while withdrawing money from bank: Family members say they have reconciled, bank will pay 100,000 yuan.
6 m ago
Goldman Sachs raises its GDP growth forecasts for South Korea and Vietnam in 2025.
6 m ago
Goldman Sachs raised its forecasts for the economic growth of South Korea and Vietnam in 2025, citing reduced U.S. tariff risks. Economists Goohoon Kwon and Andrew Tilton stated in a research report that they have revised South Korea's economic growth forecast from 0.7% to 1.1%. The forecast for Vietnam's economic growth is now 5.5%, up from the previous 5.3%.
7 m ago
Hong Kong stocks surging | Four Rings Pharmaceuticals (00460.HK) up more than 6% as two new drugs independently developed by its subsidiary Xuanzhu Biological for two indications are approved for market listing application.
See all latest